

Thank You

This PowerPoint document contains the images that you requested.

Copyright Notice

All Online Service materials, including, without limitation, text, pictures, graphics and other files and the selection and arrangement thereof are copyrighted materials of Ovid or its licensors, all rights reserved. Except for the Authorized Use specified above, you may not copy, modify or distribute any of the Online Service materials. You may not "mirror" any material contained on this Online Service on any other server. Any unauthorized use of any material contained on this Online Service may violate copyright laws, trademark laws, the laws of privacy and publicity and communications regulations and statutes.

Table 1

	Ν	%	Anti-EMM
Age (years)			Dean, Nich
Median	59		Ziober, Bar
Range	40-75		Anti Conce
Tumor site			DOI: 10.109
Oral cavity	7	31.8	
Oropharynx	12	54.5	
Neck	2	9.2	
Sinus	1	4.5	Table 1 Pat
Stage			10010 2 1 0
1	0	0	
Ш	3	13.6	
ш	0	0	
IV	19	86.4	

Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Dean, Nichole; Knowles, Joseph; Helman, Emily; Aldridge, oszi; Carroll, William; Magnuson, Jeffery; Clemons, Lisa; Ziober, Barry; Rosenthal, Eben

Anti-Cancer Drugs. 21(9):861-867, October 2010. DOI: 10.1097/CAD.0b013e32833d1a11

Table 1 Patient characteristics

Ovid<mark>SP</mark>

 $\ensuremath{\mathbb{C}}$ 2010 Lippincott Williams & Wilkins, Inc. Published by Lippincott Williams & Wilkins, Inc.

Table 2

Patient ID	TNM classification	Stage	ATP level (% of control)	Р
1	T4N2c	IV	40	< 0.001*
2	T3N2b	IV	47	0.002*
3	TxN2c	IV	48	< 0.001*
4	TxN3	IV	33	< 0.001*
5	T4N2b	IV	78	0.31
6	T4N2c	IV	27	< 0.001*
7	T4N2c	IV	44	0.004*
8	T4N0	IV	68	0.09
9	T2N2b	IV	60	0.15
10	T4N2b	IV	75	0.42
11	T2N0	Ш	58	0.12
12	T4N2b	IV	42	0.01*
13	T4N0	IV	63	0.04*
14	T4N0	IV	68	0.26
15	T4N0	IV	32	0.02*
16	T4N2c	IV	90	0.79
17	T2N2c	IV	65	0.21
18	T4N2b	IV	90	0.11
19	T2N0	Ш	70	0.37

OvidSP

😣 Wolters Kluwer

Health

Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Dean, Nichole; Knowles, Joseph; Helman, Emily; Aldridge, Joszi; Carroll, William; Magnuson, Jeffery; Clemons, Lisa; Ziober, Barry; Rosenthal, Eben
Anti-Cancer Drugs. 21(9):861-867, October 2010. DOI: 10.1097/CAD.0b013e32833d1a11

Table 2 Head and neck cancer patient ATP levels after treatment with CNTO3899 (100 [mu]g/ml)TNM, tumor node metastasis.*P value <0.05, statistically significant.

Fig. 1



🖲 "Wolters Kluwer

Health

OvidSP

Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Dean, Nichole; Knowles, Joseph; Helman, Emily; Aldridge, Joszi; Carroll, William; Magnuson, Jeffery; Clemons, Lisa; Ziober, Barry; Rosenthal, Eben Anti-Cancer Drugs. 21(9):861-867, October 2010. DOI: 10.1097/CAD.0b013e32833d1a11

Fig. 1 Viability of ex-vivo control tissue slices (n=6) at 24, 48, and 72 h compared to mean ATP level at time zero.

Fig. 2



Wolters Kluwer

Health

OvidSP

Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Dean, Nichole; Knowles, Joseph; Helman, Emily; Aldridge,

Joszi; Carroll, William; Magnuson, Jeffery; Clemons, Lisa; Ziober, Barry; Rosenthal, Eben

Anti-Cancer Drugs. 21(9):861-867, October 2010. DOI: 10.1097/CAD.0b013e32833d1a11

Fig. 2 Tissue slice cytotoxicity assays in head and neck squamous cell carcinoma patient specimens cultured with varying concentrations of CNTO3899 (0, 50, 100, and 200 [mu]g/ml). Six replicate slices were prepared per treatment group. A significant reduction in ATP levels was obtained with the treatment of 100 [mu]g/ml anti-extracellular matrix metalloproteinase inducer monoclonal antibody in patients 12,13, and 15.

Fig. 3



Wolters Kluwer

Health

OvidSP

Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model.

Dean, Nichole; Knowles, Joseph; Helman, Emily; Aldridge, Joszi; Carroll, William; Magnuson, Jeffery; Clemons, Lisa; Ziober, Barry; Rosenthal, Eben

Anti-Cancer Drugs. 21(9):861-867, October 2010. DOI: 10.1097/CAD.0b013e32833d1a11

Fig. 3 Comparison of anti-extracellular matrix metalloproteinase inducer antibody and cetuximabinduced cytotoxicity in head and neck squamous cell carcinoma patient specimens. (a) Cytotoxicity curve for head and neck cancer tissue slices (n=6 per treatment group) treated with varying concentrations of cetuximab (C225) (0, 5, 10, and 20 [mu]g/ml). A significant reduction in ATP levels was obtained with 10 [mu]g/ml. (b) Side-byside comparison of CNTO3899 (100 [mu]g/ml) and C225 (10 [mu]g/ml)-treated tissue specimens for all patients as a percentage of control. No significant difference was observed between mean ATP levels for anti-extracellular matrix metalloproteinase inducer (57%) and cetuximab (45%)-treated tumor specimens (P=0.13).

© 2010 Lippincott Williams & Wilkins, Inc. Published by Lippincott Williams & Wilkins, Inc.



OvidSP

Wolters Kluwer

Health

Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model.

Dean, Nichole; Knowles, Joseph; Helman, Emily; Aldridge, Joszi; Carroll, William; Magnuson, Jeffery; Clemons, Lisa; Ziober, Barry; Rosenthal, Eben

Anti-Cancer Drugs. 21(9):861-867, October 2010. DOI: 10.1097/CAD.0b013e32833d1a11

Fig. 4 Anti-extracellular matrix metalloproteinase inducer (EMMPRIN) monoclonal antibody induces caspase-mediated apoptosis; treatment response correlates with EMMPRIN expression. (a) Tissue specimens maintain intact tumor cells with surrounding vasculature and stroma on hematoxylin and eosin (H&E) staining. An increase in apoptosis in treated (100 [mu]g/ml CNTO3899) (77%) versus untreated slices (30%, PP=0.06) following treatment with anti-EMMPRIN monoclonal antibody. (c) CNTO3899 stimulates caspasemediated apoptosis. Control and CNTO3899 treated tissue specimens were analyzed for caspase-3 and caspase-8 expression. An increase in caspase-3 expression was observed in both patients following treatment (PP<0.001).